December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

18.73 USD +3.87 (+26.04%)
Official Closing Price Updated: 7:59 PM EST, Jan 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aurinia Pharm Ord

< Previous 1 2 3 4 5 6 7 8 Next >
Technical Snapshots for These Biotech Stocks -- Gilead Sciences, Aurinia Pharma, Esperion Therapeutics, and Alexion Pharma
From PR Newswire
Aurinia Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, presented additional data from its... 
From Business Wire News Releases
Aurinia to Participate in Late Breaking Oral Presentations at Two Upcoming Scientific Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that is has been selected to present late... 
From Business Wire News Releases
Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that the first... 
From Business Wire News Releases
Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights
Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights 
From Business Wire News Releases
The Growth of the Global Pharmaceuticals Market
FinancialBuzz.com News Commentary 
From PR Newswire
Pharma Industry Veteran Dr. George Milne Joins Aurinia’s Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the appointment of... 
From Business Wire News Releases
Aurinia to Present at Bloom Burton & Co. Healthcare Conference
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its Chief Executive Officer, Richard M. Glickman, will present at the Bloom Burton & Co. Healthcare Conference in Toronto,... 
From Business Wire News Releases
Aurinia Releases Additional 48-Week Data from the AURA-LV Study During Late-Breaking Session at the National Kidney Foundation 2017 Spring Clinical Meetings
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, today announced additional 48-week... 
From Business Wire News Releases
Biotech Stocks on Investors' Radar -- Gilead Sciences, Aurinia Pharma, Mast Therapeutics, and Novavax
From PR Newswire
Aurinia Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (“Aurinia” or the “Company”) today announced that it has signed a Definitive Agreement (“the Agreement”) granting Merck Animal Health, known as MSD... 
From Business Wire News Releases
Aurinia to Host Investor Event and Webcast on April 20th in Orlando, FL
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX:AUP) today announced that it will host an Investor Event during the National Kidney Foundation Spring Clinical Meeting on April 20, 2017 at 6:00pm... 
From Business Wire News Releases
Aurinia Announces Development Plans for Voclosporin in Europe and Japan
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), today announced the outcome of discussions with both the European Medicines Agency (EMA) and the Pharmaceutical and... 
From Business Wire News Releases
Aurinia Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the 48-week... 
From Business Wire News Releases
Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the closing of its... 
From Business Wire News Releases
Aurinia Announces Presentation at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the AURION... 
From Business Wire News Releases
Aurinia Prices US$150.5 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the pricing of its... 
From Business Wire News Releases
Aurinia Announces Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has... 
From Business Wire News Releases
Aurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights
Aurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights 
From Business Wire News Releases
Aurinia Announces Acceptance of Voclosporin Late-Breaking Presentation at the National Kidney Foundation 2017 Spring Clinical Meetings
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that its... 
From Business Wire News Releases
Aurinia to Present at Cowen and Company 37th Annual Healthcare Conference
Aurinia to Present at Cowen and Company 37th Annual Healthcare Conference 
From Business Wire News Releases
Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced top-line results... 
From Business Wire News Releases
Technical Reports on Biotech Stocks -- ZIOPHARM Oncology, Aurinia Pharma, Arena Pharma, and Marinus Pharma
From PR Newswire
Aurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the results of a... 
From Business Wire News Releases
Aurinia’s New CEO, Richard Glickman, to Present at Leerink Partners 6th Annual Global Healthcare Conference
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its newly appointed Chief Executive Officer, Richard M. Glickman and Celia Economides, Associate Vice President, Investor... 
From Business Wire News Releases
Aurinia Announces Appointment of Company Founder, Dr. Richard M. Glickman, as its New Chief Executive Officer
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced its Board of... 
From Business Wire News Releases
The Biotech Market Grows as Demand for New Therapeutics Increases
From PR Newswire
Aurinia Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has... 
From Business Wire News Releases
Aurinia Pharmaceuticals to Participate in Upcoming Conferences
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that Michael Martin, Chief Operating Officer, and Celia Economides, Associate VP of Investor Relations, will participate in the... 
From Business Wire News Releases
Aurinia Closes US$28 Million Financing
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the "Company"), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has closed... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.